Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared ...

Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso combination versus Tagrisso alone.

Reported topline data results in July from the multi-center, international ASPEN-06 Phase 2 clinical trial (NCT05002127) ...

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial) ...

Another treatment your doctor may try for your EGFR-positive NSCLC is ramucirumab (Cyramza) with erlotinib (Tarceva). You get ramucirumab through an IV, and you take erlotinib by mouth.

Giovenzio Genestreti; Francesco Grossi; Carlo Genova; Marco A Burgio; Alberto Bongiovanni; Giampaolo Gavelli; Marco Bartolotti; Monica Di Battista; Giovanna Cavallo; Alba A Brandes S-1 is an oral ...

In its upcoming report, Eli Lilly (LLY) is predicted by Wall Street analysts to post quarterly earnings of $1.53 per share, reflecting an increase of 1430% compared to the same period last year.

Data were summarized with the search of 'colorectal' and 'antibody' as of August 2012 at ClinicalTrials.gov [202]. EGFR: EGF receptor; mAb: Monoclonal antibody; VEGFR: VEGF receptor. The authors ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of ...